

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司*

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liabilities)

(Stock code: 0660)

CLARIFICATION ANNOUNCEMENT CONTINUING CONNECTED TRANSACTION

Reference is made to the announcement of Wai Chun Bio-Technology Limited dated 18 December 2019 (the “Announcement”) in relation to the New Tenancy Agreement was entered into between WCH as landlord and Wai Chun Incorporation Limited, a wholly-owned subsidiary of the Company as tenant. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context otherwise requires. The board of directors of the Company has come to notice that due to an inadvertent mistake, the information in relation to the monthly rentals payable under the Agreements on page 2 of the Announcement is incorrect. The correct information is as follows:

The annual cap for the rentals of the Premises, being the maximum aggregate amount payable to the landlord under the Agreements for each of the two years ending 31 December 2020 is HK\$3,662,400, HK\$3,700,000 respectively.

By Order of the Board
Wai Chun Bio-Technology Limited
Lam Ching Kui
Chairman and Chief Executive Officer

Hong Kong, 7 January 2020

As at the date of this announcement, the Board comprises one executive Director, namely Mr. Lam Ching Kui (Chairman and Chief Executive Officer), and two independent non-executive Directors, namely Mr. Chan Chun Wai, Tony and Mr. Hau Pak Man.

** for identification purpose only*